Eyenovia
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 57
- Market Cap
- $43.8M
- Website
- http://www.eyenovia.com
- Introduction
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Eyenovia Provides Update on Phase 3 CHAPERONE Study
Eyenovia's CHAPERONE Phase 3 study fails to meet primary endpoint of less than 0.5 diopter progression in visual acuity over three years. The independent Data Review Committee found no significant difference in myopia progression between treatment arms and placebo. Eyenovia plans to discontinue the study, review data, and evaluate next steps.
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Eyenovia reported Q3 2024 net loss of $7.9 million ($0.11 per share), with operating expenses up 10.6% to $7.2 million. Key developments include U.S. launch of clobetasol propionate ophthalmic suspension 0.05%, Phase 3 CHAPERONE study for MicroPine in pediatric myopia, and Mydcombi registration batches in second-generation Optejet device. Cash position was $7.2 million, with $10.7 million raised in net proceeds. Mydcombi expanded to 230 new offices from April to September 2024.
Eyenovia, Inc. Latest Stock News & Market Updates
Eyenovia (EYEN) develops next-gen topical eye treatments via its Microdose Array Print (MAP) platform, focusing on precision-targeted ocular delivery systems like Optejet. Key products include Mydcombi™ and FDA-approved clobetasol propionate ophthalmic suspension 0.05%. The company also has a pipeline with MicroPine for myopia and Apersure for presbyopia. Strategic collaborations and FDA approvals highlight Eyenovia’s innovative approach to ophthalmic care.
More companies share upcoming AAO presentation information
The 2024 American Academy of Ophthalmology meeting in Chicago will feature presentations on clinical trial data from Alkeus Pharmaceuticals, Annexon, Inc., Atsena Therapeutics, Avirmax Biopharma, Inc., Beacon Therapeutics, Belite Bio, Eyenovia, LENZ Therapeutics, Nanoscope Therapeutics, Inc., and ZEISS Medical Technology.
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American ...
Eyenovia presents Phase 3 study results of clobetasol propionate suspension 0.05% at AAO 2024 Expo, demonstrating efficacy and safety for post-surgical inflammation and pain, leading to FDA approval and U.S. launch.
Eyenovia Announces Presentation of Phase 3 Clobetasol Study
Eyenovia announced its clobetasol propionate suspension 0.05% (APP13007) presentation at the AAO 2024 Expo, detailing a successful Phase 3 study (CPN-302) leading to FDA approval for post-surgical inflammation and pain treatment. Clobetasol is now commercially available.
Eyenovia announces commercial availability of clobetasol propionate ophthalmic
Eyenovia launched Clobetasol propionate 0.05% for post-operative inflammation and pain in the US, approved by FDA in March 2024. Clobetasol, derived from Formosa's APNT, offers a twice-daily dosing regimen, generating strong interest among eye doctors for its efficacy and safety.
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate
Eyenovia announces U.S. launch of Clobetasol, an FDA-approved ophthalmic steroid for post-operative inflammation and pain, generating strong interest among surgeons. Clobetasol offers efficacy, safety, and a convenient dosing regimen, with streamlined distribution to bypass insurance complications.
© Copyright 2024. All Rights Reserved by MedPath